Reducing Dietary Acid With Food Versus Oral Alkali in People With Chronic Kidney Disease (ReDACKD)

Launched by DYLAN MACKAY · Oct 28, 2021

Keywords

ClinConnect Summary

The ReDACKD trial is studying how eating more fruits and vegetables can help people with chronic kidney disease (CKD) who also have a condition called metabolic acidosis. Metabolic acidosis happens when acids build up in the body because the kidneys are not working well. The usual treatment is a medicine called sodium bicarbonate, but it doesn’t always work for everyone and can cause side effects. This trial aims to see if a diet rich in alkalizing foods, which are fruits and vegetables that can help balance acids, can be an effective and more natural way to manage this condition.

To take part in this trial, participants need to be adults aged 18 or older who have specific kidney function measurements and signs of metabolic acidosis. They must be able to communicate in English and give their consent to participate. The trial is currently looking for volunteers in Winnipeg and Halifax. If someone joins the study, they can expect to receive fruits and vegetables delivered to their home as part of the treatment. It’s important to note that certain health conditions or recent medical events may exclude some individuals from participating. This trial offers a new approach to managing metabolic acidosis and may lead to better options for patients with chronic kidney disease.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participant is willing and able to give informed consent for participation in the trial
• • Male or Female, aged 18 years or above
• • Participants who have an eGFR between 15 and 40 ml/min/1.73m2
• • Two consecutive measurements of serum bicarbonate of 14 to 22 mEq/L
• • Systolic and diastolic blood pressure \<160/100 mmHg
• • Serum potassium \<5.3 mmol/L
• • Hemoglobin A1c below ≤ 11%
• • Are registered in the nephrology clinic in Winnipeg or Halifax
• • Participants are able to communicate in English and provide written informed consent
• Exclusion Criteria:
• • Anuria, dialysis or acute kidney injury/acute kidney failure in the 3 months prior to screening
• • Chronic obstructive pulmonary disease that requires the participant to be on oxygen
• • New York Heart Association Class 3-4 Heart failure symptoms or heart, liver or renal transplant
• • A myocardial infarction or stroke within the last 6 months
• • Unable to consume study treatments or control, such as swallowing or GI issues
• • Participants who have participated in another research trial involving an investigational product in the past 12 weeks
• • Currently on potassium binding therapy
• • Female participant who is pregnant or on lactating